144 related articles for article (PubMed ID: 14982042)
1. Influence of uveal melanoma therapy on patients' quality of life: a psychological study.
Chabert S; Velikay-Parel M; Zehetmayer M
Acta Ophthalmol Scand; 2004 Feb; 82(1):25-31. PubMed ID: 14982042
[TBL] [Abstract][Full Text] [Related]
2. Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients.
van Beek JGM; Buitendijk GHS; Timman R; Muller K; Luyten GPM; Paridaens D; Naus NC; Kiliç E
Acta Ophthalmol; 2018 Dec; 96(8):841-848. PubMed ID: 30284368
[TBL] [Abstract][Full Text] [Related]
3. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study.
Brandberg Y; Kock E; Oskar K; af Trampe E; Seregard S
Eye (Lond); 2000 Dec; 14(Pt 6):839-46. PubMed ID: 11584839
[TBL] [Abstract][Full Text] [Related]
4. The use of semistructured interviews to assess quality of life impacts for patients with uveal melanoma.
Kopp BC; Crump RT; Weis E
Can J Ophthalmol; 2017 Apr; 52(2):181-185. PubMed ID: 28457288
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment.
Klingenstein A; Fürweger C; Mühlhofer AK; Leicht SF; Schaller UC; Muacevic A; Wowra B; Hintschich C; Eibl KH
Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):1005-12. PubMed ID: 26573389
[TBL] [Abstract][Full Text] [Related]
6. Translation and validation of the Polish version of the EORTC QLQ-OPT30 module for the assessment of health-related quality of life in patients with uveal melanoma.
Chmielowska K; Tomaszewski KA; Pogrzebielski A; Brandberg Y; Romanowska-Dixon B
Eur J Cancer Care (Engl); 2013 Jan; 22(1):88-96. PubMed ID: 22966840
[TBL] [Abstract][Full Text] [Related]
7. Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis.
Schuermeyer I; Maican A; Sharp R; Bena J; Triozzi PL; Singh AD
JAMA Ophthalmol; 2016 Jan; 134(1):51-6. PubMed ID: 26539659
[TBL] [Abstract][Full Text] [Related]
8. [Psychological aspects and quality of life in uveal melanoma patients during the treatment process by ocular bulb remotion].
Amaro TA; Yazigi L; Erwenne C
Arq Bras Oftalmol; 2006; 69(6):889-94. PubMed ID: 17273685
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma.
Gollrad J; Rabsahl C; Riechardt AI; Heufelder J; Stroux A; Goerling U; Joussen A; Budach V; Boehmer D
Radiat Oncol; 2021 Sep; 16(1):174. PubMed ID: 34496895
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in the follow-up of uveal melanoma patients after CyberKnife treatment.
Klingenstein A; Fürweger C; Nentwich MM; Schaller UC; Foerster PI; Wowra B; Muacevic A; Eibl KH
Melanoma Res; 2013 Dec; 23(6):481-8. PubMed ID: 24048223
[TBL] [Abstract][Full Text] [Related]
11. Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma.
Akbaba S; Foerster R; Nicolay NH; Arians N; Bostel T; Debus J; Hauswald H
Radiat Oncol; 2018 Aug; 13(1):140. PubMed ID: 30071857
[TBL] [Abstract][Full Text] [Related]
12. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
Gündüz K; Shields CL; Shields JA; Cater J; Freire JE; Brady LW
Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
[TBL] [Abstract][Full Text] [Related]
13. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma.
Seibel I; Cordini D; Hager A; Tillner J; Riechardt AI; Heufelder J; Davids AM; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1787-92. PubMed ID: 27376824
[TBL] [Abstract][Full Text] [Related]
14. Long-term uveal melanoma survivors: measuring their quality of life.
Frenkel S; Rosenne H; Briscoe D; Hendler K; Bereket R; Molcho M; Pe'er J
Acta Ophthalmol; 2018 Jun; 96(4):e421-e426. PubMed ID: 29369538
[TBL] [Abstract][Full Text] [Related]
15. Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.
Tarmann L; Wackernagel W; Ivastinovic D; Schneider M; Winkler P; Langmann G
PLoS One; 2017; 12(8):e0183833. PubMed ID: 28859118
[TBL] [Abstract][Full Text] [Related]
16. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool.
Aziz HA; Singh N; Bena J; Wilkinson A; Singh AD
JAMA Ophthalmol; 2016 Jun; 134(6):615-20. PubMed ID: 27101414
[TBL] [Abstract][Full Text] [Related]
17. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
18. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.
Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
Br J Ophthalmol; 1996 Aug; 80(8):732-9. PubMed ID: 8949719
[TBL] [Abstract][Full Text] [Related]
19. One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma.
Furdova A; Strmen P; Waczulikova I; Chorvath M; Sramka M; Slezak P
Eur J Ophthalmol; 2012; 22(2):226-35. PubMed ID: 21534252
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma.
Sikuade MJ; Salvi S; Rundle PA; Errington DG; Kacperek A; Rennie IG
Eye (Lond); 2015 Sep; 29(9):1194-8. PubMed ID: 26160531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
